|Bid||25.73 x 1300|
|Ask||28.40 x 800|
|Day's Range||25.71 - 27.77|
|52 Week Range||10.26 - 33.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.88|
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced progress updates for its wholly owned, next-generation Bicycle Toxin Conjugates (BTCs) targeting oncological indications, as well as its novel, fully synthetic Bicycle tumor-targeted immune cell agonists (TICAs™).
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
In this article we will analyze whether Bicycle Therapeutics plc (NASDAQ:BCYC) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]